Whole Brain Radiation With or Without Erlotinib for Brain Metastases From Non-Small Cell Lung Cancer

Overview

To determine if erlotinib given orally along with concurrent whole brain irradiation in lung cancer patients with brain metastases improves median overall survival and enhances local control compared to those treated with WBRT alone, without significantly increasing the risk of side effects or lowering quality of life.

Endpoints Primary: • To determine if erlotinib given orally along with concurrent WBRT in lung cancer patients with brain metastases, improves median overall survival compared to those treated with WBRT alone. Secondary: * To confirm the safety profile of erlotinib along with concurrent WBRT, in the context of treating central nervous system malignancies. * To evaluate if erlotinib along with concurrent WBRT increases local control rate as measured by MRI at 8 weeks, compared to WBRT alone. * To evaluate if erlotinib along with concurrent WBRT increases time to neurologic progression of disease based on neuropsychological assessment at baseline, at 8 and 20 weeks after WBRT. * To evaluate quality of life parameters in patients treated with WBRT alone vs concomitant erlotinib and WBRT * To evaluate if mutation status has impact on the above mentioned parameters Trial design Open multicenter randomized phase II trial. Patients Patients \> 18 years with histologically confirmed NSCLC and brain metastases verified on either CT or MRI, not eligible for neurosurgery or stereotactic radiation therapy. Trial treatment Patients will be randomized 1:1 to either treatment arm A or B. * Arm A: WBRT 3 Gy x10 alone. * Arm B: WBRT 3 Gy x10 and erlotinib given concomitantly, 150 mg p.o. daily from the day before radiation, until the last day of radiation. Number of patients 150 patients will be included, 75 in each arm

Conditions

Interventions

Eligibility

Locations (1)